Viracta Therapeutics Statistics
Share Statistics
Viracta Therapeutics has 39.74M
shares outstanding. The number of shares has increased by 1.2%
in one year.
| Shares Outstanding | 39.74M |
| Shares Change (YoY) | 1.2% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 9.1% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 55,000 |
| FTD / Avg. Volume | 5.91% |
Short Selling Information
The latest short interest is 2.69M, so undefined% of the outstanding
shares have been sold short.
| Short Interest | 2.69M |
| Short % of Shares Out | n/a |
| Short % of Float | 9.61% |
| Short Ratio (days to cover) | 1.85 |
Valuation Ratios
The PE ratio is -0.43 and the forward
PE ratio is -0.4.
Viracta Therapeutics's PEG ratio is
0.
| PE Ratio | -0.43 |
| Forward PE | -0.4 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 1.2 |
| P/FCF Ratio | -0.55 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Viracta Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.43,
with a Debt / Equity ratio of 1.4.
| Current Ratio | 1.43 |
| Quick Ratio | 1.43 |
| Debt / Equity | 1.4 |
| Debt / EBITDA | -0.55 |
| Debt / FCF | -0.64 |
| Interest Coverage | -13.69 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,963,769.23 |
| Employee Count | 26 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -98.08% in the
last 52 weeks. The beta is 0.23, so Viracta Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.23 |
| 52-Week Price Change | -98.08% |
| 50-Day Moving Average | 0.05 |
| 200-Day Moving Average | 0.23 |
| Relative Strength Index (RSI) | 41.49 |
| Average Volume (20 Days) | 930,876 |
Income Statement
| Revenue | n/a |
| Gross Profit | -492K |
| Operating Income | -50.69M |
| Net Income | -51.06M |
| EBITDA | -46.86M |
| EBIT | -47.35M |
| Earnings Per Share (EPS) | -1.32 |
Full Income StatementBalance Sheet
The company has 12.32M in cash and 25.56M in
debt, giving a net cash position of -13.24M.
| Cash & Cash Equivalents | 12.32M |
| Total Debt | 25.56M |
| Net Cash | -13.24M |
| Retained Earnings | -265.93M |
| Total Assets | 21.96M |
| Working Capital | -6.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -39.89M
and capital expenditures -138K, giving a free cash flow of -40.03M.
| Operating Cash Flow | -39.89M |
| Capital Expenditures | -138K |
| Free Cash Flow | -40.03M |
| FCF Per Share | -1.04 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
